Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA PET/CT in Prostate Cancer Biochemical Relapse
NCT02920229Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Nov 2015
- Primary completion
- Oct 2020
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Sensitivity of 68Ga-PSMA PET/CT at 24 months. Started Nov 2015; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02920229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920229.